会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them
    • 尼古丁乙酰胆碱受体配体及其制备和使用方法
    • US20080132486A1
    • 2008-06-05
    • US10558607
    • 2004-06-09
    • Alan P. KozikowskiJohn L. MusachioKenneth J. KellarYingxian XiaoZhi-Liang Wei
    • Alan P. KozikowskiJohn L. MusachioKenneth J. KellarYingxian XiaoZhi-Liang Wei
    • A61K31/55A61K31/4745C07D471/14
    • C07D471/18C07D487/08
    • One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.
    • 本发明的一个方面涉及作为烟碱乙酰胆碱受体配体的杂环化合物。 本发明的第二方面涉及本发明化合物用于调节哺乳动物烟碱乙酰胆碱受体的用途。 本发明还涉及本发明化合物用于治疗患有阿尔茨海默病,帕金森病,运动障碍,图雷特综合征,精神分裂症,注意力缺陷障碍,焦虑,疼痛,抑郁,强迫症,化学物质滥用的哺乳动物的用途 酒精中毒,记忆缺陷,假性痴呆,甘ser综合征,偏头痛,贪食症,肥胖症,经前期综合征或晚期黄体期综合征,烟草滥用,创伤后综合征,社交恐惧症,慢性疲劳综合征,早泄,勃起障碍,神经性厌食症, 睡眠障碍,自闭症,多发性或三叉神经痛。
    • 7. 发明申请
    • 10-Substituted Cytisine Derivatives and Methods of Use Thereof
    • 10取代的Cytisine衍生物及其使用方法
    • US20100048606A1
    • 2010-02-25
    • US12295157
    • 2007-03-29
    • Alan P. KozikowskiWerner TueckmantelSheela ChellappanKenneth J. KellarYingxian Xiao
    • Alan P. KozikowskiWerner TueckmantelSheela ChellappanKenneth J. KellarYingxian Xiao
    • A61K31/439C07D471/18
    • C07D471/18
    • The present invention relates to substituted cytisine compounds that are useful in treating diseases impacted by a nicotinic ACh receptor. One aspect of the invention relates to 10-substituted cytisine compounds. In certain instances, the cytisine is substituted in the 10-position by an alkyl, aryl or aralkyl group. The present invention also relates to a pharmaceutical composition comprises the substituted cytisine compound or the 10-substituted cytisine compound. The invention also relates to a method of modulation a nicotinic ACh receptor in a mammal, comprising the step of administering to a mammal in need thereof a therapeutically effective amount of a substituted cytisine. In certain instances, the substituted cytisine is a 10-substituted cytisine. Another aspect of the present invention relates a method of treating a disease impacted by a nicotinic ACh receptor, comprising the step of administering to a mammal in need thereof a therapeutically effective amount of a substituted cytisine. In certain instances, the substituted cytisine is a 10-substituted cytisine.
    • 本发明涉及可用于治疗受烟碱性ACh受体影响的疾病的取代的仙培酮化合物。 本发明的一个方面涉及10-取代的仙客来化合物。 在某些情况下,通过烷基,芳基或芳烷基在十位置替代赤藓酸。 本发明还涉及药物组合物,其包含取代的仙客来化合物或10-取代的仙客来化合物。 本发明还涉及一种调节哺乳动物中烟碱性ACh受体的方法,其包括向有需要的哺乳动物施用治疗有效量的取代的氰尿酸的步骤。 在某些情况下,取代的洋甘菊是一种10-取代的胞苷。 本发明的另一方面涉及一种治疗由烟碱性ACh受体影响的疾病的方法,其包括向有需要的哺乳动物施用治疗有效量的取代的洋甘菊的步骤。 在某些情况下,取代的洋甘菊是一种10-取代的胞苷。
    • 8. 发明授权
    • Ligands for nicotinic acetylcholine receptors, and methods of making and using them
    • 烟碱乙酰胆碱受体的配体,以及制造和使用它们的方法
    • US08030300B2
    • 2011-10-04
    • US10558607
    • 2004-06-09
    • Alan P. KozikowskiJohn L. MusachioKenneth J. KellarYingxian XiaoZhi-Liang WeiHong Fan
    • Alan P. KozikowskiJohn L. MusachioKenneth J. KellarYingxian XiaoZhi-Liang WeiHong Fan
    • A61K31/4427C07D401/12
    • C07D471/18C07D487/08
    • One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.
    • 本发明的一个方面涉及作为烟碱乙酰胆碱受体配体的杂环化合物。 本发明的第二方面涉及本发明化合物用于调节哺乳动物烟碱乙酰胆碱受体的用途。 本发明还涉及本发明化合物用于治疗患有阿尔茨海默病,帕金森病,运动障碍,图雷特综合征,精神分裂症,注意力缺陷障碍,焦虑,疼痛,抑郁,强迫症,化学物质滥用的哺乳动物的用途 酒精中毒,记忆缺陷,假性痴呆,甘ser综合征,偏头痛,贪食症,肥胖症,经前期综合征或晚期黄体期综合征,烟草滥用,创伤后综合征,社交恐惧症,慢性疲劳综合征,早泄,勃起障碍,神经性厌食症, 睡眠障碍,自闭症,多发性或三叉神经痛。
    • 9. 发明授权
    • Combination of huperzine and nicotinic compounds as a neuroprotective agent
    • 组合石杉碱和烟碱化合物作为神经保护剂
    • US06369052B1
    • 2002-04-09
    • US09910819
    • 2001-07-23
    • Kenneth J. KellarAlan P. Kozikowski
    • Kenneth J. KellarAlan P. Kozikowski
    • A61K3155
    • A61K31/465A61K31/44A61K2300/00
    • The present invention provides compositions and methods for treating, preventing, or reversing neuronal dysfunction including cognitive decline, such as cognitive decline associated with aging and minimal cognitive impairment; severe neurodegenerative disorders, such as Alzheimer's disease; and neuronal dysfunction associated with loss of motor skills, such as Parkinson's disease and amyotrophic lateral sclerosis. The compositions and methods of the invention can also treat or prevent neuronal dysfunction resulting from CNS injury, such as stroke, spinal-cord injury, and peripheral-nerve injury. The compositions of the invention comprises a huperzine compound and a nicotinic compound.
    • 本发明提供用于治疗,预防或逆转神经元功能障碍的组合物和方法,包括认知衰退,例如与衰老相关的认知衰退和最小的认知障碍; 严重的神经变性疾病,如阿尔茨海默病; 以及与运动技能丧失相关的神经元功能障碍,例如帕金森病和肌萎缩性侧索硬化。 本发明的组合物和方法还可以治疗或预防由CNS损伤引起的神经元功能障碍,例如中风,脊髓损伤和外周神经损伤。 本发明的组合物包含石杉碱化合物和烟碱化合物。